🔎 Trials Near Me

Home › Collapsed Lung › NCT05960929

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

RecruitingPhase 3

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS: A Single-dose, Double-blind, Random Allocation, Sham-control, Clinical Trial

Who can join

29 Weeks – 36 Weeks · All sexes

Full eligibility criteria
Inclusion Criteria:

Inclusion criteria include ALL of the following:

1. Written informed consent obtained by parent or legal representative prior to or after birth
2. Gestational age at birth ≥ 29 0/7 AND ≤ 35 6/7 weeks
3. Birthweight ≥ 1,000 AND ≤ 3,500 grams
4. Age ≥ 1 hour AND ≤ 6 hours
5. Clinical diagnosis of surfactant-deficient RDS, with EITHER i. a Silverman-Anderson Retraction Score ≥ 5 (in Room Air), OR ii. signs of respiratory distress (tachypnea, retractions, grunting) AND radiographic confirmation
6. Require CPAP
7. Respiratory Severity Score (RSS) ≥ 1.25 AND ≤ 2.4
8. If subject is \>346/7 weeks' gestation a chest radiograph is required

Exclusion Criteria:

Exclusion criteria are ANY of the following:

1. Surfactant administration prior to randomization
2. Mechanical ventilation prior to randomization
3. Major congenital anomaly (suspected or confirmed)
4. Abnormality of the airway (suspected or confirmed)
5. Respiratory distress presumed secondary to an etiology other than RDS (e.g., suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy)
6. Apgar score \< 3 at 5 minutes of age
7. Umbilical cord gas pH \<7.0 or BD \> 10
8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk

About the study

The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.

What is being tested

Sponsor: ONY · Participants: 220 · Started: Jan 1, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT05960929

Locations in the U.S.

ArizonaPhoenix Children's, Phoenix
St. Josephs Hospital and Medical Center, Phoenix
CaliforniaSharp Mary Birch Hospital for Women & Newborns, San Diego
FloridaUniversity of Florida -Jacksonville, Jacksonville
HawaiiKapi'olani Medical Center for Women & Children, Honolulu
New JerseyJersey Shore University Medical Center, Neptune City
New YorkSisters of Charity Hospital, Buffalo
TennesseeWestern TN- Jackson-Madison County General Hospital, Jackson
UtahUtah Valley Hospital, Provo
WisconsinUnity Point Meriter, Madison

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.